At Resonant, our team of researchers, physicians, and business leaders is united by a shared mission: to translate innovative research into impactful clinical solutions.
We foster a culture of empathy, collaboration, and innovation, ensuring everything we do centers on advancing patient care.
A PhD candidate in Genetics, Genomics, and Biotechnology, Chad has focused his career on developing innovative healthcare solutions, including neurodegeneration screening tools.
An Associate Professor of Cell Biology and Physiology at BYU, Tim is a leader in leveraging epigenetics to develop clinically actionable diagnostic tools.
With expertise in accounting and finance from leadership roles at startups and firms like Ernst & Young and PwC, Adam drives financial strategy and operational efficiency.
As Co-Director of the KU Alzheimer’s Disease Research Center, Dr. Burns ensures Resonant’s research remains clinically relevant and aligned with translational goals.
With nearly a decade of experience developing epigenetic-based assays, Ryan brings deep bioinformatics expertise to support Resonant’s technology development.
With a background in nursing and healthcare administration, Tanner leads sales strategy with a proven track record of delivering multimillion-dollar results in healthcare and biotech.
Integrity lies at the core of how we conduct our research, manage our business, and interact with each other and the communities we serve. This means upholding high ethical standards, being honest in our communications, and embracing responsibility in our decisions and their impacts.
Our commitment to innovation drives us to develop more effective solutions for patients with neurodegenerative diseases. We embrace leading technologies and novel research methodologies to create solutions with the potential to expedite diagnoses and significantly improve patient outcomes.
Empathy guides our approach to healthcare. We are dedicated to understanding and addressing the needs of patients, families, and caregivers affected by neurodegenerative diseases. This commitment not only influences our product development, but also the way we support each other within our team.
Our goal is to empower patients. We are developing tools to detect biomarkers of neurodegeneration earlier in disease progression. But these tools aren't just about detecting diseases earlier. They're about giving control back to the patients, empowering them to make informed decisions that enhance their quality of life.
We prioritize thorough validation of our tests to ensure that healthcare professionals and patients can make informed decisions based on dependable test results. Our rigorous approach supports better health outcomes, disease management, and treatment planning.
